Domestic and international markets in Asia surging as CPHI & PMEC China welcomes 60,000 attendees and 3500 exhibitors SHANGHAI and AMSTERDAM , May 31, 2024 /PRNewswire/ — CPHI & PMEC China ( June 19-21 st ) returns to the Shanghai New International Expo Center amid soaring demand across the pharmaceutical supply chain in Asia . China , already the primary source of pharmaceutical ingredients and starting materials globally, has also seen domestic demand improve rapidly post-pandemic. Consequentially, exhibitors are reporting robust growth across most Asian countries, with expected attendance significantly up year-on-year.

This latest positive boon for the region follows rapid rises in domestic pharma share prices, record drug approvals [60 in 2023] and unprecedented numbers of out-licencing deals in China – all reported in the last few months [1][2][3] . Jenny Leung , Regional Manager, Informa Markets, commenting on the event’s continued success: “Last year, we had a record-breaking attendance, and we anticipate an even more international platform this year with numbers up once again. China remains unrivalled as ‘the’ source of ingredients and starting materials, while its domestic market is also booming.

Regional drug makers are expanding exports and increasingly serving China’s consistently growing domestic healthcare demand.” CPHI & PMEC China is at the heart of the world’s second-largest pharma economy and its largest manufacturing centre. In total, 3500.